Cited by 622DNA Repair MechanismsPARP inhibition in cancer therapyChromatin Remodeling and Cancer

The DOI matches its Crossref record; 151 of the 151 references it cites were found in a registry or an index.

The effects of deregulated DNA damage signalling on cancer chemotherapy response and resistance

Bouwman, Peter, Jonkers, Jos·2012·Nature Reviews Cancer

Open this paper in CoChat — free account

Abstract

Tumours with specific DNA repair defects can be completely dependent on back-up DNA repair pathways for their survival. This dependence can be exploited therapeutically to induce synthetic lethality in tumour cells. For instance, homologous recombination (HR)-deficient tumours can be effectively targeted by DNA double-strand break-inducing agents. However, not all HR-defective tumours respond equally well to this type of therapy. Tumour cells may acquire resistance by invoking biochemical mechanisms that reduce drug action or by acquiring additional alterations in DNA damage response pathways. A thorough understanding of these processes is important for predicting treatment response and for the development of novel treatment strategies that prevent the emergence of therapy-resistant tumours.

Integrity signals

Registry

Crossref · 10.1038/nrc3342

Cites

151 of 151 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

1 retracted

RETRACTED: Human SIRT6 Promotes DNA End Resection Through CtIP Deacetylation
Kaidi, A., Weinert, B. T., Choudhary, C., & Jackson, S. P. (2010) · Science · doi:10.1126/science.1192049 · Cited by 366
Retracted
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications
Sørlie, T., Perou, C. M., Tibshirani, R. J., Aas, T., Geisler, S. B., Johnsen, H., Hastie, T. J., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191367098 · Cited by 11,506
Gene expression profiling predicts clinical outcome of breast cancer
van 't Veer, L. J., Dai, H., van de Vijver, M. J., He, Y. D., Hart, A. A. M., Mao, M., Peterse, H. L., van der Kooy, K., Marton, M. J., Witteveen, A. T., et al. (2002) · Nature · doi:10.1038/415530a · Cited by 9,536
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683
Glioma stem cells promote radioresistance by preferential activation of the DNA damage response
Bao, S., Wu, Q., McLendon, R. E., Hao, Y., Shi, Q., Hjelmeland, A. B., Dewhirst, M. W., Bigner, D. D., & Rich, J. N. (2006) · Nature · doi:10.1038/nature05236 · Cited by 6,517
A Strong Candidate for the Breast and Ovarian Cancer Susceptibility Gene BRCA1
Miki, Y., Swensen, J. J., Shattuck-Eidens, D. M., Futreal, P. A., Harshman, K., Tavtigian, S. V., Liu, Q., Cochran, C., Bennett, L. M., Ding, W., et al. (1994) · Science · doi:10.1126/science.7545954 · Cited by 6,069
Multidrug resistance in cancer: role of ATP–dependent transporters
Gottesman, M. M., Fojo, T., & Bates, S. E. (2002) · Nature Reviews Cancer · doi:10.1038/nrc706 · Cited by 5,536
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
Bryant, H. E., Schultz, N., Thomas, H. D., Parker, K. M., Flower, D., Lopez, E., Kyle, S., Meuth, M., Curtin, N. J., & Helleday, T. (2005) · Nature · doi:10.1038/nature03443 · Cited by 5,198
The resurgence of platinum-based cancer chemotherapy
Kèlland, L. R. (2007) · Nature reviews. Cancer · doi:10.1038/nrc2167 · Cited by 4,733
In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661

Flagged first, then by citations

Show all 151 references

Sorted by citations

Cancer drug resistance: an evolving paradigm
Holohan, C., Van Schaeybroeck, S., Longley, D. B., & Johnston, P. G. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3599 · Cited by 4,681
Mechanisms of DNA damage, repair, and mutagenesis
Chatterjee, N., & Walker, G. C. (2017) · Environmental and Molecular Mutagenesis · doi:10.1002/em.22087 · Cited by 2,039
“VC 2017Wiley Periodicals, Inc. Environmental andMolecular Mutagenesis 58:235^263 (2017) deregulated, which increases mutagenesis and genomic instability, thereby promoting cancer progression [Bouw- man and Jonkers, 2012; Ghosal and Chen, 2013; Wolters and Schumacher, 2013].”
DNA Damage Sensing by the ATM and ATR Kinases
Marechal, A., & Zou, L. (2013) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a012716 · Cited by 1,514
Treatment of muscle‐invasive and advanced bladder cancer in 2020
Patel, V. G., Oh, W. K., & Galsky, M. D. (2020) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21631 · Cited by 1,038
Rad51-mediated replication fork reversal is a global response to genotoxic treatments in human cells
Zellweger, R., Dalcher, D., Mutreja, K., Berti, M., Schmid, J. A., Herrador, R., Vindigni, A., & Lopes, M. (2015) · The Journal of Cell Biology · doi:10.1083/jcb.201406099 · Cited by 691
Therapeutic opportunities within the DNA damage response
Pearl, L. H., Schierz, A. C., Ward, S. E., Al-Lazikani, B., & Pearl, F. M. G. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3891 · Cited by 587
AIE Luminogens for Bioimaging and Theranostics: From Organelles to Animals
Qian, J., & Tang, B. Z. (2017) · Chem · doi:10.1016/j.chempr.2017.05.010 · Cited by 578
Defects in DNA Repair Genes Predict Response to Neoadjuvant Cisplatin-based Chemotherapy in Muscle-invasive Bladder Cancer
Plimack, E. R., Dunbrack, R. L., Brennan, T. A., Andrake, M., Zhou, Y., Serebriiskii, I. G., Slifker, M. J., Alpaugh, K. R., Dulaimi, E., Palma, N. A., et al. (2015) · European Urology · doi:10.1016/j.eururo.2015.07.009 · Cited by 521
Overcoming cancer therapeutic bottleneck by drug repurposing
Zhang, Z., Zhou, L., Xie, N., Nice, E. C., Zhang, T., Cui, Y., & Huang, C. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00213-8 · Cited by 544
DNA repair pathways and cisplatin resistance: an intimate relationship
Rocha, C. R. R., Silva, M. M., Quinet, A., Cabral-Neto, J. B., & Menck, C. F. M. (2018) · Clinics · doi:10.6061/clinics/2018/e478s · Cited by 475
Cancer stem cells and chemoresistance: The smartest survives the raid
Zhao, J. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.02.008 · Cited by 446
New Insights into Mechanisms of Cisplatin Resistance: From Tumor Cell to Microenvironment
Chen, S., & Chang, J. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20174136 · Cited by 443
Machine learning approaches to drug response prediction: challenges and recent progress
Adam, G. A., Rampášek, L., Safikhani, Z., Smirnov, P., Haibe‐Kains, B., & Goldenberg, A. (2020) · npj Precision Oncology · doi:10.1038/s41698-020-0122-1 · Cited by 459
Molecular aspects of cancer cell resistance to chemotherapy
Rebucci, M., & Michiels, C. (2013) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.02.017 · Cited by 423
DNA Damage/Repair Management in Cancers
Alhmoud, J. F., Woolley, J. F., Moustafa, A. A., & Malki, M. I. (2020) · Cancers · doi:10.3390/cancers12041050 · Cited by 410
Reversal of multidrug resistance by stimuli-responsive drug delivery systems for therapy of tumor
Yin, Q., Shen, J., Zhang, Z., Yu, H., & Li, Y. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.04.011 · Cited by 366
DNA helicases involved in DNA repair and their roles in cancer
Brosh, R. M. (2013) · Nature reviews. Cancer · doi:10.1038/nrc3560 · Cited by 361
Therapeutic Targeting of CDK12/CDK13 in Triple-Negative Breast Cancer
Quereda, V., Bayle, S., Vena, F., Frydman, S. M., Monastyrskyi, A., Roush, W. R., & Duckett, D. R. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.09.004 · Cited by 352
A Forward Vision for Chemodynamic Therapy: Issues and Opportunities
Zhao, P., Li, H., & Bu, W. (2023) · Angewandte Chemie International Edition · doi:10.1002/anie.202210415 · Cited by 342
Drug resistance in cancer: mechanisms and tackling strategies
Haider, T., Pandey, V., Banjare, N., Gupta, P. N., & Soni, V. (2020) · Pharmacological Reports · doi:10.1007/s43440-020-00138-7 · Cited by 282
Targeting DNA damage response in cancer therapy
Hosoya, N., & Miyagawa, K. (2014) · Cancer Science · doi:10.1111/cas.12366 · Cited by 309
Histone deacetylase inhibitor (HDACI) mechanisms of action: Emerging insights
Bose, P., Dai, Y., & Grant, S. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.04.004 · Cited by 287
ATR inhibition induces synthetic lethality and overcomes chemoresistance in TP53- or ATM-defective chronic lymphocytic leukemia cells
Kwok, M., Davies, N., Agathanggelou, A., Smith, E., Oldreive, C., Petermann, E., Stewart, G. S., Brown, J., Lau, A., Pratt, G., et al. (2015) · Blood · doi:10.1182/blood-2015-05-644872 · Cited by 288
Endoplasmic reticulum stress signaling and chemotherapy resistance in solid cancers
Avril, T., Vauléon, É., & Chevet, É. (2017) · Oncogenesis · doi:10.1038/oncsis.2017.72 · Cited by 274
Functional interplay between ATM/ATR-mediated DNA damage response and DNA repair pathways in oxidative stress
Yan, S., Sorrell, M., & Berman, Z. (2014) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-014-1666-4 · Cited by 247
Organelle-specific initiation of cell death
Galluzzi, L., Bravo-San Pedro, J. M., & Kroemer, G. (2014) · Nature Cell Biology · doi:10.1038/ncb3005 · Cited by 239
Targeting tumour-supportive cellular machineries in anticancer drug development
Dobbelstein, M., & Moll, U. M. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4201 · Cited by 233
The mechanism(s) of action of antioxidants: From scavenging reactive oxygen/nitrogen species to redox signaling and the generation of bioactive secondary metabolites
Hunyadi, A. (2019) · Medicinal Research Reviews · doi:10.1002/med.21592 · Cited by 244
Clinical cancer genomic profiling
Chakravarty, D., & Solit, D. B. (2021) · Nature Reviews Genetics · doi:10.1038/s41576-021-00338-8 · Cited by 241
Selective Autophagy Regulates Cell Cycle in Cancer Therapy
Zheng, K., He, Z., Kitazato, K., & Wang, Y. (2018) · Theranostics · doi:10.7150/thno.30308 · Cited by 229
Temozolomide-associated hypermutation in gliomas
Choi, S., Yu, Y., Grimmer, M., Wahl, M. T., Chang, S. M., & Costello, J. (2018) · Neuro-Oncology · doi:10.1093/neuonc/noy016 · Cited by 221
Acetylation of MORC2 by NAT10 regulates cell-cycle checkpoint control and resistance to DNA-damaging chemotherapy and radiotherapy in breast cancer
Liu, H., Liu, Y., Yang, F., Zhang, L., Zhang, F., Hu, X., Shao, Z., & Li, D. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkaa130 · Cited by 210
The Novel ATR Inhibitor BAY 1895344 Is Efficacious as Monotherapy and Combined with DNA Damage–Inducing or Repair–Compromising Therapies in Preclinical Cancer Models
Wengner, A. M., Siemeister, G., Lücking, U., Lefranc, J., Wortmann, L., Lienau, P., Bader, B., Bömer, U., Moosmayer, D., Eberspächer, U., et al. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-19-0019 · Cited by 208
Protective role of miR-155 in breast cancer through RAD51 targeting impairs homologous recombination after irradiation
Gasparini, P., Lovat, F., Fassan, M., Casadei, L., Cascione, L., Jacob, N. K., Carasi, S., Palmieri, D., Costinean, S., Shapiro, C. L., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1402604111 · Cited by 216
ATM signalling and cancer
Cremona, C. A., & Behrens, A. (2013) · Oncogene · doi:10.1038/onc.2013.275 · Cited by 219
Therapeutic strategies to overcome cisplatin resistance in ovarian cancer
Song, M., Cui, M., & Liu, K. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114205 · Cited by 219
Hybrid Drugs—A Strategy for Overcoming Anticancer Drug Resistance?
Szumilak, M., Wiktorowska‐Owczarek, A., & Stańczak, A. (2021) · Molecules · doi:10.3390/molecules26092601 · Cited by 216
Interplay between Fanconi anemia and homologous recombination pathways in genome integrity
Michl, J., Zimmer, J., & Tarsounas, M. (2016) · The EMBO Journal · doi:10.15252/embj.201693860 · Cited by 217
Organelle-Specific Initiation of Autophagy
Sica, V., Galluzzi, L., Bravo-San Pedro, J. M., Izzo, V., Maiuri, M. C., & Kroemer, G. (2015) · Molecular Cell · doi:10.1016/j.molcel.2015.07.021 · Cited by 205
DNA damage tolerance: a double-edged sword guarding the genome.
Ghosal, G., & Chen, J. (2013) · PubMed · doi:10.3978/j.issn.2218-676x.2013.04.01 · Cited by 215
Drugging Ras GTPase: a comprehensive mechanistic and signaling structural view
Lu, S., Jang, H., Gu, S., Zhang, J., & Nussinov, R. (2016) · Chemical Society Reviews · doi:10.1039/c5cs00911a · Cited by 188
Harnessing DNA Double-Strand Break Repair for Cancer Treatment
Trenner, A., & Sartori, A. A. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01388 · Cited by 205
USP1 deubiquitinase: cellular functions, regulatory mechanisms and emerging potential as target in cancer therapy
García‐Santisteban, I., Peters, G. J., Giovannetti, E., & Rodríguez, J. A. (2013) · Molecular Cancer · doi:10.1186/1476-4598-12-91 · Cited by 191
Deep Insight of Design, Mechanism, and Cancer Theranostic Strategy of Nanozymes
Yang, L. G., Dong, S., Gai, S., Yang, D., Ding, H., Feng, L., Yang, G., Rehman, Z., & Yang, P. (2023) · Nano-Micro Letters · doi:10.1007/s40820-023-01224-0 · Cited by 191
Dual-Target Inhibitors Based on HDACs: Novel Antitumor Agents for Cancer Therapy
Liu, T., Wan, Y., Xiao, Y., Xia, C., & Duan, G. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00491 · Cited by 181
Chronic oxidative stress promotes H2AX protein degradation and enhances chemosensitivity in breast cancer patients
Gruosso, T., Mieulet, V., Cardon, M., Bourachot, B., Kieffer, Y., Devun, F., Dubois, T., Dutreix, M., Vincent‐Salomon, A., Miller, K. M., et al. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201505891 · Cited by 179
Cancer drug resistance: redox resetting renders a way
Liu, Y., Li, Q., Zhou, L., Xie, N., Nice, E. C., Zhang, H., Huang, C., & Lei, Y. (2016) · Oncotarget · doi:10.18632/oncotarget.8600 · Cited by 182
Large-scale determination of absolute phosphorylation stoichiometries in human cells by motif-targeting quantitative proteomics
Tsai, C.-F., Wang, Y.-T., Yen, H., Tsou, C., Ku, W., Lin, P.-Y., Chen, H., Nesvizhskii, A. I., Ishihama, Y., & Chen, Y. (2015) · Nature Communications · doi:10.1038/ncomms7622 · Cited by 173
Genomic landscape of DNA repair genes in cancer
Chae, Y. K., Anker, J. F., Carneiro, B. A., Chandra, S., Kaplan, J. B., Kalyan, A., Santa-Maria, C. A., Platanias, L. C., & Giles, F. J. (2016) · Oncotarget · doi:10.18632/oncotarget.8196 · Cited by 174
Identifying the target genes of SUPPRESSOR OF GAMMA RESPONSE 1, a master transcription factor controlling DNA damage response in Arabidopsis
Ogita, N., Okushima, Y., Tokizawa, M., Yamamoto, Y. Y., Tanaka, M., Seki, M., Makita, Y., Matsui, M., Yoshiyama, K., Sakamoto, T., et al. (2018) · The Plant Journal · doi:10.1111/tpj.13866 · Cited by 164
Clonal evolution in hematological malignancies and therapeutic implications
Landau, D. A., Carter, S. L., Getz, G. A., & Wu, C. J. (2013) · Leukemia · doi:10.1038/leu.2013.248 · Cited by 173
Inhibition of Topoisomerase (DNA) I (TOP1): DNA Damage Repair and Anticancer Therapy
Xu, Y., & Her, C. (2015) · Biomolecules · doi:10.3390/biom5031652 · Cited by 169
Functional Ex Vivo Assay to Select Homologous Recombination–Deficient Breast Tumors for PARP Inhibitor Treatment
Naipal, K. A. T., Verkaik, N. S., Ameziane, N., van Deurzen, C. H. M., ter Brugge, P., Meijers, M., Sieuwerts, A. M., Martens, J. W. M., O’Connor, M. J., Vrieling, H., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0571 · Cited by 168
Self-citation
Molecular Pathways: How Can BRCA-Mutated Tumors Become Resistant to PARP Inhibitors?
Bouwman, P., & Jonkers, J. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0225 · Cited by 166
Self-citation
A polydopamine-based platform for anti-cancer drug delivery
Ambekar, R. S., & Kandasubramanian, B. (2019) · Biomaterials Science · doi:10.1039/c8bm01642a · Cited by 162
Histone deacetylase inhibitor treatment induces ‘BRCAness’ and synergistic lethality with PARP inhibitor and cisplatin against human triple negative breast cancer cells
Ha, K., Fiskus, W. C., Choi, D. S., Bhaskara, S., Cerchietti, L. C. A., Devaraj, S. G. T., Shah, B., Sharma, S., Chang, J. C., Melnick, A. M., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2154 · Cited by 158
DNA damage response and resistance of cancer stem cells
Abad, E., Graifer, D., & Lyakhovich, A. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.01.008 · Cited by 148
Oncogenic MicroRNAs: Key Players in Malignant Transformation
Frixa, T., Donzelli, S., & Blandino, G. (2015) · Cancers · doi:10.3390/cancers7040904 · Cited by 151
Cancer chemoresistance; biochemical and molecular aspects: a brief overview
Kachalaki, S., Ebrahimi, M., Khosroshahi, L. M., Mohammadinejad, S., & Baradaran, B. (2016) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2016.03.025 · Cited by 151
A Platinum(IV) Anticancer Prodrug Targeting Nucleotide Excision Repair To Overcome Cisplatin Resistance
Wang, Z., Xu, Z., & Zhu, G. (2016) · Angewandte Chemie International Edition · doi:10.1002/anie.201608936 · Cited by 141
Regulation of Ca2+ Signaling for Drug-Resistant Breast Cancer Therapy with Mesoporous Silica Nanocapsule Encapsulated Doxorubicin/siRNA Cocktail
Wang, S., Liu, X., Chen, S., Liu, Z., Zhang, X., Liang, X., & Li, L. (2018) · ACS Nano · doi:10.1021/acsnano.8b05639 · Cited by 141
MIR34Aregulates autophagy and apoptosis by targetingHMGB1in the retinoblastoma cell
Liu, K., Huang, J. X., Xie, M., Yu, Y. H., Zhu, S., Kang, R., Cao, L., Tang, D., & Duan, X. (2014) · Autophagy · doi:10.4161/auto.27418 · Cited by 137
Systemic, perioperative management of muscle-invasive bladder cancer and future horizons
Funt, S. A., & Rosenberg, J. E. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.188 · Cited by 134
Identification of ANXA2 (annexin A2) as a specific bleomycin target to induce pulmonary fibrosis by impeding TFEB-mediated autophagic flux
Wang, K., Zhang, T., Lei, Y., Li, X., Jiang, J., Lan, J., Liu, Y., Chen, H., Gao, W., Xie, N., et al. (2017) · Autophagy · doi:10.1080/15548627.2017.1409405 · Cited by 134
The interplay between DNA repair and autophagy in cancer therapy
Zhang, D., Tang, B., Xie, X., Xiao, Y., Yang, S., & Zhang, J. (2015) · Cancer Biology & Therapy · doi:10.1080/15384047.2015.1046022 · Cited by 132
Therapeutic progress and challenges for triple negative breast cancer: targeted therapy and immunotherapy
Yang, R., Li, Y., Wang, H., Qin, T., Yin, X., & Ma, X. (2022) · Molecular Biomedicine · doi:10.1186/s43556-022-00071-6 · Cited by 141
Use of poly ADP-ribose polymerase [PARP] inhibitors in cancer cells bearing DDR defects: the rationale for their inclusion in the clinic
Cerrato, A., Morra, F., & Celetti, A. (2016) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-016-0456-2 · Cited by 132
Complex DNA repair pathways as possible therapeutic targets to overcome temozolomide resistance in glioblastoma
Yoshimoto, K., Mizoguchi, M., Hata, N., Murata, H., Hatae, R., Amano, T., Nakamizo, A., & Sasaki, T. (2012) · Frontiers in Oncology · doi:10.3389/fonc.2012.00186 · Cited by 126
The role of metabolism and tunneling nanotube-mediated intercellular mitochondria exchange in cancer drug resistance
Hekmatshoar, Y., Nakhle, J., Galloni, M., & Vignais, M. (2018) · Biochemical Journal · doi:10.1042/bcj20170712 · Cited by 127
Downregulation of Meg3 enhances cisplatin resistance of lung cancer cells through activation of the WNT/β-catenin signaling pathway
Xia, Y., He, Z., Liu, B., Wang, P., & CHEN, Y. (2015) · Molecular Medicine Reports · doi:10.3892/mmr.2015.3897 · Cited by 122
Mesoporous Magnetic Gold “Nanoclusters” as Theranostic Carrier for Chemo-Photothermal Co-therapy of Breast Cancer
Peng, J., Qi, T., Liao, J., Chu, B., Yang, Q., Qu, Y., Li, W., Li, H., Luo, F., & Qian, Z. (2014) · Theranostics · doi:10.7150/thno.7869 · Cited by 119
Oncogenic miR-181a/b affect the DNA damage response in aggressive breast cancer
Bisso, A., Faleschini, M., Zampa, F., Capaci, V., Santa, J. D., Santarpia, L., Piazza, S., Cappelletti, V., Daidone, M. G., Agami, R., et al. (2013) · Cell Cycle · doi:10.4161/cc.24757 · Cited by 120
Therapeutic landscape in mutational triple negative breast cancer
Shi, Y., Jin, J., Ji, W., & Guan, X. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0850-9 · Cited by 118
Crystal structure, biochemical and cellular activities demonstrate separate functions of MTH1 and MTH2
Carter, M., Jemth, A., Hagenkort, A., Page, B. D. G., Gustafsson, R., Griese, J. J., Gad, H., Valerie, N. C. K., Desroses, M., Boström, J., et al. (2015) · Nature Communications · doi:10.1038/ncomms8871 · Cited by 119
Analysis of PARP inhibitor toxicity by multidimensional fluorescence microscopy reveals mechanisms of sensitivity and resistance
Michelena, J., Lezaja, A., Teloni, F., Schmid, T., Imhof, R., & Altmeyer, M. (2018) · Nature Communications · doi:10.1038/s41467-018-05031-9 · Cited by 117
The DNA Damage Response and Inflammation in Cancer
Klapp, V., Álvarez-Abril, B., Leuzzi, G., Kroemer, G., Ciccia, A., & Galluzzi, L. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-1220 · Cited by 115
A dual-responsive, hyaluronic acid targeted drug delivery system based on hollow mesoporous silica nanoparticles for cancer therapy
Huang, L., Liu, J., Gao, F., Cheng, Q., Lü, B., Zheng, H. S., Xu, H., Xu, P., Zhang, X., & Zeng, X. (2018) · Journal of Materials Chemistry B · doi:10.1039/c8tb00989a · Cited by 107
Multifunctional nanoplatforms co-delivering combinatorial dual-drug for eliminating cancer multidrug resistance
Xiao, W., Song, M., Li, W., Huang, J., Yang, G. Y., & Wang, Y. (2021) · Theranostics · doi:10.7150/thno.59342 · Cited by 108
CARM1 Inhibition Enables Immunotherapy of Resistant Tumors by Dual Action on Tumor Cells and T Cells
Kumar, S., Zeng, Z., Bagati, A., Tay, R. E., Sanz, L. A., Hartono, S. R., Ito, Y., Abderazzaq, F. O., Hatchi, E., Jiang, P., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1144 · Cited by 106
MicroRNA-21: a therapeutic target for reversing drug resistance in cancer
Hong, L., Han, Y., Zhang, Y., Zhang, H., Zhao, Q., Wu, K., & Fan, D. (2013) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2013.819853 · Cited by 104
MicroRNA-495-3p inhibits multidrug resistance by modulating autophagy through GRP78/mTOR axis in gastric cancer
Chen, S., Wu, J., Jiao, K., Wu, Q., Ma, J., Chen, D., Kang, J., Zhao, G., Shi, Y., Fan, D., et al. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-0950-x · Cited by 100
Clinical Candidates Targeting the ATR–CHK1–WEE1 Axis in Cancer
Górecki, L., Andrš, M., & Korábečný, J. (2021) · Cancers · doi:10.3390/cancers13040795 · Cited by 107
Prolyl Isomerase PIN1 Regulates DNA Double-Strand Break Repair by Counteracting DNA End Resection
Steger, M., Murina, O., Hühn, D., Ferretti, L. P., Walser, R., Hänggi, K., Lafranchi, L., Neugebauer, C., Paliwal, S., Janščák, P., et al. (2013) · Molecular Cell · doi:10.1016/j.molcel.2013.03.023 · Cited by 100
A New View of Pathway-Driven Drug Resistance in Tumor Proliferation
Nussinov, R., Tsai, C., & Jang, H. (2017) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2017.02.001 · Cited by 94
Temozolomide treatment outcomes and immunotherapy efficacy in brain tumor
Hotchkiss, K. M., & Sampson, J. H. (2020) · Journal of Neuro-Oncology · doi:10.1007/s11060-020-03598-2 · Cited by 93
Deubiquitylating Enzymes and DNA Damage Response Pathways
Jacq, X., Kemp, M. I., Martin, N. M. B., & Jackson, S. P. (2013) · Cell Biochemistry and Biophysics · doi:10.1007/s12013-013-9635-3 · Cited by 90
Alleviation of Multidrug Resistance by Flavonoid and Non-Flavonoid Compounds in Breast, Lung, Colorectal and Prostate Cancer
Costea, T., Vlad, O., Miclea, L. C., Ganea, C., Szöllõsi, J., & Mocanu, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21020401 · Cited by 93
DNA damage responses in cancer stem cells: Implications for cancer therapeutic strategies
Wang, Q. (2015) · World Journal of Biological Chemistry · doi:10.4331/wjbc.v6.i3.57 · Cited by 92
A fine-scale dissection of the DNA double-strand break repair machinery and its implications for breast cancer therapy
Liu, C., Srihari, S., Cao, K. L., Chenevix‐Trench, G., Simpson, P. T., Ragan, M. A., & Khanna, K. K. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku284 · Cited by 91
microRNAs and Acute Myeloid Leukemia Chemoresistance: A Mechanistic Overview
Gabra, M., & Salmena, L. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00255 · Cited by 90
Estrone-modified pH-sensitive glycol chitosan nanoparticles for drug delivery in breast cancer
Yang, H., Tang, C., & Yin, C. (2018) · Acta Biomaterialia · doi:10.1016/j.actbio.2018.04.020 · Cited by 89
Development of an assay to measure mutagenic non-homologous end-joining repair activity in mammalian cells
Bindra, R. S., Goglia, A. G., Jasin, M., & Powell, S. N. (2013) · Nucleic Acids Research · doi:10.1093/nar/gkt255 · Cited by 89
Olaparib modulates DNA repair efficiency, sensitizes cervical cancer cells to cisplatin and exhibits anti-metastatic property
Prasad, C. B., Prasad, S. B., Yadav, S. S., Pandey, L. K., Singh, S., Pradhan, S., & Narayan, G. (2017) · Scientific Reports · doi:10.1038/s41598-017-13232-3 · Cited by 84
The paradigm of drug resistance in cancer: an epigenetic perspective
Adhikari, S., Bhattacharya, A., Adhikary, S., Singh, V., Gadad, S. S., Roy, S., & Das, C. (2022) · Bioscience Reports · doi:10.1042/bsr20211812 · Cited by 91
Double‐strand DNA break repair: molecular mechanisms and therapeutic targets
Tan, J., Sun, X., Zhao, H., Guan, H., Gao, S., & Zhou, P. (2023) · MedComm · doi:10.1002/mco2.388 · Cited by 101
Actionable gene-based classification toward precision medicine in gastric cancer
Ichikawa, H., Nagahashi, M., Shimada, Y., Hanyu, T., Ishikawa, T., Kameyama, H., Kobayashi, T., Sakata, J., Yabusaki, H., Nakagawa, S., et al. (2017) · Genome Medicine · doi:10.1186/s13073-017-0484-3 · Cited by 87
Tumour microenvironment-responsive semiconducting polymer-based self-assembling nanotheranostics
Yáng, Z., Dai, Y., Shan, L., Shen, Z., Wang, Z., Yung, B. C., Jacobson, O., Liu, Y., Tang, W., Wang, S., et al. (2018) · Nanoscale Horizons · doi:10.1039/c8nh00307f · Cited by 87
DNA Repair Gene Patterns as Prognostic and Predictive Factors in Molecular Breast Cancer Subtypes
Santarpia, L., Iwamoto, T., Leo, A. D., Hayashi, N., Bottai, G., Stampfer, M. R., André, F., Turner, N. C., Symmans, W. F., Hortobágyi, G. N., et al. (2013) · The Oncologist · doi:10.1634/theoncologist.2013-0163 · Cited by 87
Targeting nuclear kinases in cancer: Development of cell cycle kinase inhibitors
Pitts, T. M., Davis, S. L., Eckhardt, S. G., & Bradshaw‐Pierce, E. L. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.12.010 · Cited by 87
A nuclease-mimetic platinum nanozyme induces concurrent DNA platination and oxidative cleavage to overcome cancer drug resistance
Li, F., Sun, H., Ren, J., Zhang, B., Hu, X., Fang, C., Lee, J., Gu, H., & Ling, D. (2022) · Nature Communications · doi:10.1038/s41467-022-35022-w · Cited by 93

Authors: Bouwman, P., & Jonkers, J.
Affiliations: The Netherlands Cancer Institute (NL)
Corresponding author: Jonkers, Jos
ORCID: Bouwman, Peter
Jonkers, Jos
Venue: Nature Reviews Cancer
Publisher: Springer Science and Business Media LLC
Published: 2012-08-24
Volume: 12
Issue: 9
Pages: 587-598
ISSN: 1474-175X (ISSN-L)
1474-1768
DOI: 10.1038/nrc3342
OpenAlex: W1980438635
Cited by: 615
References: 151
Citations by year: 2026: 20 · 2025: 31 · 2024: 43 · 2023: 40 · 2022: 52 · 2021: 47 · 2020: 56 · 2019: 29 · 2018: 46 · 2017: 56 · 2016: 52 · 2015: 43 · 2014: 53 · 2013: 44 · 2012: 3
FWCI: 4.17
Type: journal article
Language: en
Open access: closed
Licence: www.springer.com/tdm (tdm)
Locations: Nature reviews. Cancer (publishedVersion)
PubMed (publishedVersion)
Funders: European Commission
KWF Kankerbestrijding
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › DNA Repair Mechanisms
Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
Keywords: DNA damage response, chemoresistance, synthetic lethality, homologous recombination deficiency, DNA repair deficiency, acquired drug resistance
MeSH terms: Antineoplastic Agents, DNA Damage, DNA Repair, Neoplasms, Signal Transduction, Genes, p53, Drug Resistance, Neoplasm

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

The effects of deregulated DNA damage signalling on cancer chemotherapy response and resistance

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks